Literature DB >> 12684397

Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

Udit N Verma1, Rama M Surabhi, Aurelia Schmaltieg, Carlos Becerra, Richard B Gaynor.   

Abstract

The beta-catenin and APC genes are key components of the Wnt signaling pathway. Mutation of these genes results in increased levels of the beta-catenin protein, which is associated with enhanced cellular proliferation and the development of both colon polyps and colon cancer. Recently, a technique known as RNA interference has been successfully adapted to mammalian cells so that it is now possible to specifically decrease the expression of cellular genes after transfection of annealed small interfering 21-mer RNAs. In the current study, we used small interfering RNA (siRNA) directed against beta-catenin to determine the effects of decreasing the high constitutive levels of this protein in colon cancer cell lines with mutations in either beta-catenin or APC. Our studies demonstrate that siRNA directed against beta-catenin markedly decreased beta-catenin-dependent gene expression and inhibited cellular proliferation as reflected in the reduced growth of these colon cancer cells both in soft agar and in nude mice. These results indicate that siRNA can target specific factors whose expression is altered in malignancy and may have the potential as a therapeutic modality to treat human cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684397

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  98 in total

1.  siRNA targeting Livin decreases tumor in a xenograft model for colon cancer.

Authors:  Bo-Young Oh; Ryung-Ah Lee; Kwang Ho Kim
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

Review 2.  Nanomedicine in GI.

Authors:  Hamed Laroui; David S Wilson; Guillaume Dalmasso; Khalid Salaita; Niren Murthy; Shanthi V Sitaraman; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-09       Impact factor: 4.052

3.  Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with beta-catenin or GRIP1.

Authors:  Catherine K Yang; Jeong Hoon Kim; Hongwei Li; Michael R Stallcup
Journal:  J Biol Chem       Date:  2005-12-12       Impact factor: 5.157

Review 4.  The canonical Wnt signalling pathway and its APC partner in colon cancer development.

Authors:  Jean Schneikert; Jürgen Behrens
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

5.  An inducible T7 RNA polymerase-dependent plasmid system.

Authors:  Matthias Hamdorf; Heide Muckenfuss; Ulrich Tschulena; Stephan Pleschka; Ralf Sanzenbacher; Klaus Cichutek; Egbert Flory
Journal:  Mol Biotechnol       Date:  2006-05       Impact factor: 2.695

Review 6.  Nonviral delivery of synthetic siRNAs in vivo.

Authors:  Saghir Akhtar; Ibrahim F Benter
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

7.  Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis.

Authors:  Bumseok Kim; Qingquan Tang; Partha S Biswas; Jun Xu; Raymond M Schiffelers; Frank Y Xie; Aslam M Ansari; Puthupparampil V Scaria; Martin C Woodle; Patrick Lu; Barry T Rouse
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

8.  Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer.

Authors:  Snehal Naik; Robin S Dothager; Jayne Marasa; Cory L Lewis; David Piwnica-Worms
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

9.  Vinculin regulates cell-surface E-cadherin expression by binding to beta-catenin.

Authors:  Xiao Peng; Laura E Cuff; Cort D Lawton; Kris A DeMali
Journal:  J Cell Sci       Date:  2010-01-19       Impact factor: 5.285

Review 10.  Self-assembled lipid nanomedicines for siRNA tumor targeting.

Authors:  Yu-Cheng Tseng; Leaf Huang
Journal:  J Biomed Nanotechnol       Date:  2009-08       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.